We are live on ! Find out more
UTMD icon

Utah Medical Products

117 hedge funds and large institutions have $118M invested in Utah Medical Products in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 50 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

0% more funds holding

Funds holding: 117117 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

2.09% less ownership

Funds ownership: 67.62%65.54% (-2.1%)

14% less capital invested

Capital invested by funds: $136M → $118M (-$18.9M)

34% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 50

Holders
117
Holders Change
Holders Change %
0%
% of All Funds
1.42%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
10
Increased
33
Reduced
50
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BIP
1
Brandes Investment Partners
California
$19.7M +$776K +13,392 +4%
Dimensional Fund Advisors
2
Dimensional Fund Advisors
Texas
$11M -$204K -3,523 -2%
Renaissance Technologies
3
Renaissance Technologies
New York
$10.8M -$423K -7,300 -4%
BlackRock
4
BlackRock
New York
$10.3M +$273K +4,715 +3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$9.85M +$19.9K +344 +0.2%
Hotchkis & Wiley Capital Management
6
Hotchkis & Wiley Capital Management
California
$6.1M
MA
7
Minerva Advisors
Pennsylvania
$5.24M +$32.3K +557 +0.6%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$4.91M -$126K -2,166 -2%
State Street
9
State Street
Massachusetts
$3.83M -$131K -2,256 -3%
RHJA
10
Rice Hall James & Associates
California
$3.6M +$172K +2,967 +5%
Morgan Stanley
11
Morgan Stanley
New York
$2.45M -$788K -13,589 -24%
HCM
12
Huber Capital Management
California
$2.06M -$638K -11,012 -23%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$1.99M -$579K -9,989 -22%
Northern Trust
14
Northern Trust
Illinois
$1.64M -$123K -2,120 -7%
CCMINC
15
Cardinal Capital Management Inc (North Carolina)
North Carolina
$1.39M +$26.6K +459 +2%
QCM
16
Quantinno Capital Management
New York
$1.33M +$42.8K +739 +3%
EHC
17
Everett Harris & Co
California
$1.19M +$241K +4,151 +24%
BA
18
Bard Associates
Illinois
$1.02M -$149K -2,571 -12%
Millennium Management
19
Millennium Management
New York
$915K -$244K -4,208 -20%
Qube Research & Technologies (QRT)
20
Qube Research & Technologies (QRT)
United Kingdom
$855K +$104K +1,786 +13%
OSAM
21
O'Shaughnessy Asset Management
Connecticut
$834K +$19.5K +337 +2%
T. Rowe Price Associates
22
T. Rowe Price Associates
Maryland
$823K -$86K -1,484 -9%
LSV Asset Management
23
LSV Asset Management
Illinois
$754K +$29K +500 +4%
Ameriprise
24
Ameriprise
Minnesota
$750K
Fidelity Investments
25
Fidelity Investments
Massachusetts
$741K +$27.4K +473 +4%

UTMD Hedge Fund Activity: Q4 2025 in Review

117 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q4 2025, worth a combined $118M — down 14% from $136M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new UTMD positions and 9 closed out — a net gain of 1 holder — while 33 added to existing stakes and 50 trimmed.

The largest buyer was Brandes Investment Partners, adding an estimated $776K. The largest seller was Isthmus Partners, cutting an estimated $1.68M.

  • 117 institutional investors held Utah Medical Products (UTMD) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $118M of Utah Medical Products stock for Q4 2025, down 14% quarter-over-quarter.
  • 10 funds opened new Utah Medical Products positions in Q4 2025 and 9 closed out, a net change of +1 holder.
  • The largest Utah Medical Products buyer in Q4 2025 was Brandes Investment Partners, an estimated $776K added.
  • The largest Utah Medical Products seller in Q4 2025 was Isthmus Partners, an estimated $1.68M sold.

Based on aggregated 13F filings for Q4 2025.